1-4 of 4
Andy Nguyen
Close
Sort by
Journal Articles

Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

Nirmish Shah, Thokozeni Lipato, Thomas E. Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Ofelia A. Alvarez
Journal: Blood
Blood (2022) 140 (Supplement 1): 1954–1956.
https://doi.org/10.1182/blood-2022-169536
Published: 2022
Journal Articles

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Nirmish Shah, Thokozeni Lipato, Ofelia A. Alvarez, Thomas Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Irene Agodoa
Journal: Blood
Blood (2021) 138 (Supplement 1): 2052.
https://doi.org/10.1182/blood-2021-153138
Published: 2021
Journal Articles

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

M. Lia Palomba, MD, Monika P. Jun, MPH, Jacob Garcia, MD, James Lymp, PhD, November McGarvey, Matthew Gitlin, Corey Pelletier, Andy Nguyen
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-141415
Published: 2020
Journal Articles

Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study

Tanya Siddiqi, MD, Jacob Garcia, MD, Christine Dehner, Andy Nguyen, PhD, Matthew Gitlin, PharmD, Karen C. Chung, PharmD, MS, Jeremy S. Abramson, MD MMSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 319.
https://doi.org/10.1182/blood-2018-99-112214
Published: 2018